文献 メラノーマ.jp【医療者向け】:ノバルティス ファーマ株式会社

ページ内を移動するためのショートカット

NOVARTIS ONCOLOGY

稀少がん.net

文献

キーワードをチェックして「絞り込む」ボタンを押すと、該当する文献が表示されます。

悪性黒色腫のステージ
遺伝子変異等
治療法
研究の種別
発表年

対象文献

19件該当しました。

  1. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
    Long GV, et al.: Lancet 386(9992): 444-51(2015)
  2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
    Hauschild A, et al.: Lancet 380(9839): 358-65(2012)
  3. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma.
    Flaherty KT, et al.: N Engl J Med 367(2): 107-14(2012)
  4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT, et al.: N Engl J Med 367 (18):1694-703(2012)
  5. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
    Johnson DB, et al.: J Clin Oncol 32 (33) : 3697-704(2014)
  6. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose- escalation trial.
    Falchook GS, et al.: Lancet 379 (9829) : 1893-901 (2012)
  7. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib(GSK2118436) in Patients With Metastatic Melanoma.
    Ascierto PA, et al.: J Clin Oncol 31 (26) : 3205-11 (2013)
  8. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
    Long GV, et al.: Lancet Oncol 13 (11) : 1087-95 (2012)
  9. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
    Falchook GS, et al.: Lancet Oncol 13(8): 782?9 (2012)
  10. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
    Kim KB, et al.: J Clin Oncol 31(4): 482-9(2013)
  11. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D,et al.: Eur J Cancer 51(7):833-40 (2015)
  12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-l
    Grob JJ,et al.: Lancet Oncol 16(13):1389-98 (2015)
  13. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K, et al.: J Dermatol Sci 80(1):33-7(2015)
  14. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
    Carlino MS, et al.: Mol Cancer Ther 12(7):1332-42(2013)
  15. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N,et al.: Cancer Discov 4(1):61-8(2014)
  16. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.
    Lee CI, et al.:Melanoma Res 24(5):468-74(2014)
  17. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
    Menzies AM, et al.: Ann Oncol 26 (2):415-21 (2015)
  18. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV, et al.: N Engl J Med 371(20): 1877-88(2014)
  19. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, et al.: N Engl J Med 372(1): 30-9(2015)

ページトップへ戻る